SRC as a target for anti-cancer drugs

Anti-Cancer Drug Design

Volumn 11, Issue 3, 1996, Pages 175-182

  Levitzki, Alexander ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CELL CYCLE; DRUG TARGETING; GENE ACTIVATION; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE; ONCOGENE NEU; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0029994470     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. AGBOTOUNOU, W.K., LEVITZKI, A., JACQUEMIN-SABLON, A. & PIERRE, J. (1994). Effects of Tyrphostins on the activated c-src protein in NIH/3T33 cells. Molecular Pharmacology, 45, 922.
2. ANAFI, M., GAZIT, A., GILON, C., BEN-NERIAH, Y. & LEVITZKI, A. (1992). Selective interactions of transforming and normal ab1 protein with ATP, tyrosine copolymer substrates and tyrphostins. Journal of Biological Chemistry, 267, 4518.
3. BISHOP, J.M. (1987). The molecular genetics of cancer. Science, 335, 305.
4. c-src protein kinase activity in human colon carcinoma. Proceedings of the National Academy of Sciences (USA), 84(8), 2251.
5. BURKE, T.R., JR, FORD, H., OSHEROV, N., LEVITZKI, A., STEFANOVA, I., HORAK, I.D. & MARQUEZ, V.E. (1992). Arylamides of hydroxylated isoquinolines as protein-tyrosine kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 12, 1771.
6. c-src protein kinase is an early event in colonic carcinogenesis. Proceedings of the National Academy of Sciences (USA), 87, 558.
7. COURTNEIDGE, S.A., DHAND, R., PILAT, D., TWAMLEY, G.M., WATERFIELD, M.D. & ROUSSEL, M. (1993). Activation of Src family by colony stimulating factor-1, and their association with its receptor. EMBO Journal, 12, 943.
8. COUSSENS, L., YANG-FENG, Y.T., LIAO, Y.C., CHEN, E., GRAY, A., MCGRATH, J., SEEBURG, P.H., LIBERMAN, T., SCHLESSINGER, J., FRANCKE, U., LEVINSON, A. & ULLRICH U. (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogenes. Science, 230, 1132.
9. c-src tyrosine kinase activity and phosphotyrosylphosphatase activity in human colon carcinoma and normal human colon mucosal cells. Journal of Cellular Biochemistry, 35, 113.
10. DI FIORE, P.P., SEGATTO, O., TAYLOR, W.G., AARONSON, S.A. & PIERCE, J.H. (1990). EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. Science, 248, 79.
11. ELDER, G.T., FISHER, G.J., LINDQUIST, P.B., BENNET, G.L., PITTELKOW, M.R., COFFEY, R.J., ELLINGSWORTH, L., DENRYNCK, R. & VOORHEES, G.G. (1989). Overexpression of transforming growth factor in promatic epidermis. Science, 243, 811.
12. ERPEL, T. & COURTNEIDGE, S.A. (1995). Src family tyrosine kinases and cellular signal transduction pathways. Current Opinion in Cell Biology, 7, 176.
13. GAZIT, A., YAISH, P., GILON, C. & LEVITZKI, A. (1991). Tyrphostins II: Heterocyclic and a-substituted benzonemalononitrile tyrphostins as potent inhibitors of EGF receptor and erbB-2/neu tyrosine kinases. Journal of Medicinal Chemistry, 34, 1987.
14. GAZIT, A., OSHEROV, N., POSNER, I., BAR-SINAI, A., GILON, C. & LEVITZKI, A. (1993). Tyrphostin 3. Structure activity relationship studies of 5-S-aryl a-substituted benzylidenemalononitrile tyr-phostins. Journal of Medicinal Chemistry, 36, 3556.
15. HANKE, J.H., GARDINER, J.F., DOW, R.L., CHANGELIAN, P.S., BRISSETTE, W.H., WERINGER, E.J., POLLOCK, B.A. & CONNELLY, P.A. (1996). Discovery of a novel src family-selective tyrosine kinase inhibitor. Journal of Biological Chemistry, 271, 695.
16. HELDIN, C.H. & WESTERMARK, B. (1991). Platelet-derived growth factor and autocrine mechanisms of oncogenic processes. CRC Critical Reviews in Oncogenesis 2, 109.
17. KOVALENKO, M., GAZIT, A., BOHMER, A., RORSMAN, C., RONNSTRAND, L., HELDIN, C.-H., WALTENBERGER, J., BOHMER, F.-D. & LEVITZKI, A. (1994). Selective platelet-derived growth factor receptor kinase blockers reverse cis-transformation. Cancer Research, 54, 6106.
18. KYPTA, R.M., GOLDBERG, Y., ULUG, E.T. & COURTNEIDGE, S.A. (1990). Association between the PDGF receptor and members of the src family of tyrosine kinases. Cell, 62, 481.
19. LEVITZKI, A. (1990). Tyrphostins - potential antiproliferative agents and novel molecular tools. Biochemical Pharmacology, 40, 913.
20. LEVITZKI, A. (1992). Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB Journal, 6, 3275.
21. LEVITZKI, A. (1994). Signal transduction therapy: a novel approach to disease management. European Journal of Biochemistry, 226, 1.
22. LEVITZKI, A. & GAZIT, A. (1995). Tyrosine kinases inhibition: An approach to drug development. Science, 267, 1782.
23. LUGO, T.G., PENDERGAST, A.M., MULLER, A.J. & WITTE, O.N. (1990). Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science, 247, 1079.
24. c-src with two major signaling pathways in human breast cancer. Proceedings of the National Academy of Sciences (USA), 91, 83.
25. c-src in human small cell and non-small cell lung carcinomas. European Journal of Cancer, 28, 372.
26. MELLSTROM, K., BJELFMAN, C., HAMMERLING, U. & PAHLMAN, S. (1987). Expression of c-src in cultured human neuroblastoma and small-cell lung carcinoma cell lines correlates with neurocrine differentiation. Molecular and Cellular Biology, 7, 4178.
27. MUTHUSWAMY, S.K., SEGEL, P.M., DANKORT, D.L., WEBSTER, M.A. & MULLER, W.J. (1994). Mammary tumors expressing the neu proto-oncogene possess elevated c-src tyrosine kinase activity. Molecular and Cellular Biology, 14, 735.
28. NOVOGRODSKY, A., VANICHKIN, A., PATYA, M., GAZIT, A., OSHEROV, N. & LEVITZKI, A. (1994). Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors. Science, 264, 1319.
29. OSADA, H., SASAKI, M., SONODA, T. & ISONO, K (1995). Epiderstatin induces the flat reversion of NRK cells transformed by temperature-sensitive Rous sarcoma virus. Bioscience Biotechnology Biochemistry, 56, 1801.
30. OSHEROV, N. (1995). PhD Thesis, The Hebrew University of Jerusalem, Jerusalem, Israel.
31. OSHEROV, N. & LEVITZKI, A. (1994). Epidermal growth factor dependent activation of Src family kinases. European Journal of Biochemistry, 225, 1047.
32. OSHEROV, N., GAZIT, A., GILON, C. & LEVETZKI, A. (1993). Selective inhibition of the EGF and HER-2/Neu receptors by Tyrphostins. Journal of Biological Chemistry, 268, 11134.
33. OTTENHOF-KALFF, A.E., RIJKSEN, G., van BEURDEN, A.C.M., HENNIPMAN, A., MICHELS, A.A. & STAAL, G.E.J. (1992). Characterization of protein tyrosine kinases from human breast cancer - involvement of the c-src oncogene product. Cancer Research, 49, 4773.
34. OUDE WEERNINCK, P.A., OTTENHOFF-KALFF, A.E., VENDRIG, M.P., VAN BEURDEN, E.A., STAAL, G.E. & RIJKSEN, G. (1994). Functional interaction between the epidermal growth factor receptor and c-Src kinase activity. FEBS Letters, 352, 296.
35. PARK, J., MEISLER, A.I. & CARTWRIGHT, C.A. (1993). c-Yes tyrosine kinase activity in human colon carcinoma. Oncogene, 8, 2627.
36. POWIS, G. & WORKMAN, P. (1994). Signaling targets for the development of cancer drugs. Anti-Cancer Drug Design, 9, 263.
37. ROCHE, S., FUMAGALLI, S. & COURTNEIDGE, S.A. (1995). Requirement for Src family protein tyrosine kinases in G2 for fibroblast cell division. Science, 269, 1567.
38. ROSS, R. (1993). The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 362, 801.
39. SATO, K., SATO, A., AOTO, M. & FUKAMI, Y. (1995). Site-specific association of c-Src with epidermal growth factor receptor in A431 cells. Biochemical and Biophysical Research Communications, 210, 844.
40. SLAMON, D.J., CLARK, G.M., WONG, S.G., LEVIN, J.W., ULLRICH, A. & MCGUIRE, W.L. (1987). Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177.
41. SLAMON, D.J., GODOLPHIN, W., JONES, L.A., HOLT, J.A., WONG, S.G., KEITH, D.E., LEVIN, W.J., STUART, S.G., UDOVE, J., ULLRICH, A. & PRESS, M.F. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707.
42. SIOVER, D.R., BI CKER, M., LIEBEIANZ, J. & LYDON, N.B. (1995). Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. Journal of Biological Chemistry, 270, 15591.
43. VARICHKIN, A., PATYA, M., GAZIT, A., LEVITZKI, A. & NOVOGRODSKY, A. Late administration of lipophilic tryphostins prevents lipopolysaccharide toxicity. Infectious Disease, in press.
44. VOLBERG, T., ZIK, Y.. DROR, R., SABANAY, I., GILON, C., LEVITZKI, A. & . GEIGER, G. (1992). The effect of tyrosine specific protein phosphorylation on the assembly of adhesin type junctions. EMBO Journal, 11, 1733.
45. c-src activity in well and poorly differentiated human colon carcinomas and cell lines. Journal of Clinical Investigation, 90, 815.